Photocure, Salix deal

Photocure granted Salix exclusive, worldwide rights, excluding the Nordic region, to develop and commercialize Lumacan hexaminolevulinate. The fluorescence-based photodynamic diagnostic product is in Phase I/II testing to detect precancerous and cancerous lesions in the colon. Salix also gains rights to develop products for additional gastrointestinal dysplasia and cancer indications. Photocure retains rights in the Nordic region. ...